Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-SVF in Alzheimer's Disease
NCT02912169Phase 2Withdrawn
- Sponsor
- Ageless Regenerative Institute
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction in Alzheimer's disease (AD), sponsored by Ageless Regenerative Institute. Primary endpoint: Mini Mental State Examination at 6 months. Planned start Nov 2015; status: withdrawn.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02912169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912169.